← Back to list
Quviviq (daridorexant) (Revised)
Act
immediately
Effective date
Jan 1, 2024
Identified
Jun 24, 2026
Replaced. This version was replaced by Quviviq (daridorexant) (Revised) (published Jan 1, 2024).
Summary
Humana Medicare Advantage has updated its step therapy policy for Quviviq (daridorexant), an insomnia medication. Members must now have previous treatment, contraindication, or intolerance to Belsomra (suvorexant) or trazodone before Quviviq will be covered.
Get alerts when payers change rules like this one
We check Humana and other payers every day and email you when a change matches your specialty and state.
Get Humana alertsPolicy Monitoring is free. No card required.
What to do
immediately · 2 steps
01Providers treating insomnia patients must document previous treatment, contraindication, or intolerance to Belsomra (suvorexant) or trazodone tablet before prescribing Quviviq (daridorexant) for Medicare Advantage members.
02Update EMR templates to include step therapy documentation requirements.
If missed: Failure to meet criteria will result in coverage denials.
Original notice
Quviviq (daridorexant) (Revised)
mcp.humana.com · Always check the source before changing claims.